Australian National Amyloidosis Day May 8, 2024 – video now available
May 8, Australian National Amyloidosis Day is a very important day for raising awareness about the group of complicated relatively rare diseases, referred to as amyloidosis. This year the Australian [...]
Tafamidis for ATTR CA listed on the PBS from May 1
PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure.For more detailed information use this link to the PBS website. Then click on [...]
AAN Mayo Clinic Travel Grant Winners
Congratulations to the three young researchers who are heading to the International Symposium of Amyloidosis at the Mayo Clinic on AAN travel grants Photo by Leslie Beasley on Unsplash The AAN [...]
Mrs Patricia Neely – Member of the Order of Australia (AM)
Congratulations to our Pat Neely, newly appointed Member of the Order of Australia for her services for the amyloidosis community. The AAN proudly congratulates Pat Neely, a founding member [...]
PBAC recommends patisiran for ATTRv with neuropathy
Patisiran has been recommended by the Pharmaceutical Benefits Advisory Committee for those with hereditary transthyretin amyloidosis with polyneuropathy. Patisiran is an intravenous a gene silencing therapy that is given every 3 [...]
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
Abstract Background Transthyretin amyloid cardiomyopathy is characterized by the deposition of misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR stabilizer that acts to inhibit dissociation [...]
Consensus recommendations on holistic care in hereditary ATTR amyloidosis
Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life- limiting multisystem disease, affecting every aspect of a patient’s life. This online international Delphi survey aimed to evolve clinical−patient-led practical [...]
Positive progress towards Medicare funded access to Tafamidis and Patisiran for ATTR
PBAC has recommended PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure. The latest Pharmaceutical Benefits Advisory Committee (PBAC) Meeting was [...]
Coronavirus: Instructions for amyloidosis patients
Vaccination is vital to help control COVID-19 and keep you and the community well. If we in Australia with the rest of the world are going to control COVID-19 [...]
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
Authors David Adams Yukio Ando João Melo Beirão Teresa Coelho Morie A. Gertz Julian D. Gillmore Philip N. Hawkins Isabelle Lousada Ole B. Suhr Giampaolo Merlini Abstract Amyloid transthyretin (ATTR) amyloidosis with polyneuropathy (PN) is a progressive, debilitating, systemic disease wherein transthyretin protein misfolds [...]
2nd European meeting for ATTR amyloidosis
Reports from the 2nd European meeting for ATTR amyloidosis for doctors and patients from the NZ ATTR Amyloidosis Patients Association and the Australian ATTR Amyloidosis Alliance representative. This very successful fourday [...]
2019 International Myeloma Workshop
The International Myeloma Workshop was held in Boston, USA from 12th-15th September 2019. This is a conference attended by >3000 medical professionals every 2 years, where world leaders in the [...]
